BMAL1 and pancreatic neoplasm: This finding is supported by the recent studies which reported that BMAL1 overexpression can increase the sensitivity of CRC to oxaliplatin and paclitaxel in tongue squamous cell carcinoma and gemcitabine in pancreatic cancer (29–31).